PRVB News and Press, Provention Bio Inc. From 09/19/19

Provention Bio (NASDAQ: PRVB ) prices its public offering of 5M common shares at $8/share for gross proceeds of $40M. More news on: Provention Bio, Inc., Healthcare stocks news, Read more ...

OLDWICK, N.J. , Sept. 18, 2019 /PRNewswire/ -- Provention Bio, Inc., (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the pricing of its previously announced underwritten registered public offerin...

OLDWICK, N.J. , Sept. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical-stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced that management will present at the H.C. Wainwright 21 st Annual Global In...

NetworkNewsWire Editorial Coverage : Drugs play an essential role in treating anything from a mild headache to life-threatening disease — and everything in between. While effectiveness of drugs is what most often captures the spotlight, that effectiveness is closely associated with the...

OLDWICK, N.J. , Aug. 20, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today announced the appointment of Sherron Kell , MD, MPH as Senior Vice President of Clin...

The following slide deck was published by Provention Bio, Inc. in conjunction with this Read more ...

OLDWICK, N.J. , Aug. 8, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it has dosed the first patients in its PREVAIL (PRV-3279 EVAluation In L...

OLDWICK, N.J. , Aug. 6, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2019 and pr...

The FDA has granted Breakthrough Therapy Designation (BTD) to Provention Bio's (NASDAQ: PRVB ) teplizumab (PRV-031) for the prevention or delay of clinical type 1 diabetes in individuals at-risk of developing the disease. More news on: Provention Bio, Inc., Healthcare stocks news, Stocks...

OLDWICK, N.J. , Aug. 5, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq:PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Ther...